Embedded Files
The global fabry disease treatment market size is estimated to reach a value of USD 4.93 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.9% from 2024 to 2030. Rising cohort of Fabry disease, increasing adoption of novel therapies such as chaperone treatment, and potential approval of pipeline drugs including substrate reduction therapies and enzyme replacement therapies are providing a fillip to the market.
Fabry disease is a rare inherited lysosomal storage disorder caused by genetic mutation that interferes with function of alpha galactosidase enzyme. Fabry disease generally has a late onset with mild symptoms, due to which several patients are often undiagnosed. Standard of care for management of the disease is enzyme replacement therapy (ERT). Sanofi’s Fabrazyme and Shire’s Replagal are the only approved ERTs in the EU; however in the U.S., only Fabrazyme has been approved.
Focus of current clinical trials is to improve the safety and efficacy profile of ERTs and introduction of novel oral therapies that can eliminate the need for intravenous infusions. Recently, Amicus Therapeutics’ Galafold has been approved as the first oral chaperone therapy for the treatment of adults in the U.S., Canada, EU, Japan, Australia, Israel, and South Korea.
North America held the largest share in the Fabry disease treatment market in 2017, followed by Europe. The growth of the region can be attributed to higher adoption of novel therapies, favorable reimbursement policies, and better healthcare facilities. However, high cost of therapy with ERTs such as Fabrazyme is an impediment for the market in developing regions.
Curious about the Fabry Disease Treatment Market? Download your FREE sample copy now and get a sneak peek into the latest insights and trends.
Fabry Disease Treatment Market Report Highlights
• Intravenous route dominated the market with a market share of 65.9 % in 2023 and is also expected to grow at the fastest CAGR over the forecast period from 2024 to 2030.
• The enzyme replacement treatment segment dominated the market and accounted for a share of 72.3 % in 2023.
• North America commanded the leading market share of more than 45.1% in the Fabry disease treatment market, followed by Europe, in 2023
• APAC is likely to witness the fastest growth during the forecast period, followed by Latin America, due to increasing healthcare expenditure and rising patient population
Fabry Disease Treatment Market Segmentation
Grand View Research has segmented the global fabry disease treatment market on the basis on treatment, route of administration, distribution channel, and region:
Fabry Disease Treatment Outlook (Revenue, USD Million, 2018 - 2030)
• Enzyme Replacement Therapy (ERT)
• Chaperone Treatment
• Substrate Reduction Therapy (SRT)
• Others
Fabry Disease Treatment Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
• Intravenous Route
• Oral Route
Fabry Disease Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Fabry Disease Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Thailand
• Latin America
o Brazil
o Mexico
• Middle East and Africa (MEA)
o KSA
o UAE
o South Africa
o South Arabia
List Of Key Players in the Fabry Disease Treatment Market
• Sanofi S.A.
• Shire PIc.
• Amicus Therapeutics Inc.
• ISU Abxis Co Ltd.
• JCR Pharmaceuticals Co Ltd.
• Protalix Biotherapeutics Inc.
• Idorsia Pharmaceuticals Ltd.
• Avrobio Inc.
• Takeda Pharmkceutical Co Ltd.
• Chiesi Farmaceutici SpA
• Freeline Therapeutics Holdings PLC
• Yuhan Corp
• MOP Therapeutics
Order a free sample PDF of the Fabry Disease Treatment Market Intelligence Study, published by Grand View Research.
Page updated
Google Sites
Report abuse